Sun Pharmaceuticals rating – Buy- One-offs hit bottomline in Q4FY22
时间:2024-06-29 02:14:10 阅读(143)
Sun reported net loss of Rs 22.8 bn in Q4, mainly on one-offs of Rs 39.4 bn (Rs 37.2 bn of provisions related to settlement of antitrust litigation for valganciclovir, valsartan and esomeprazole, Rs 1.6 bn of provisions for settlement with various purchaser groups and Rs 563.5 m for restructuring of certain businesses). It also booked a one-off tax gain of Rs 764.2 m and FX gain of Rs 1.6 bn. Adjusting for one-offs and FX, PAT was Rs 14.2 bn (~19% below HSBCe). EBITDA margins at 23.1% fell 109bps y-o-y and 346bps q-o-q on input cost pressure and normalisation of expenses.
Traction continues for specialty sales: Global sales for the specialty products portfolio of $185 m grew ~33% y-o-y (+1% q-o-q) on strong traction in key brands Ilumya, Cequa, and Odomzo. Specialty sales in FY22 grew 42% to $673 m (13% of total revenues vs 7% in FY18). Global sales for Ilumya (incl. milestones and royalties) reached $315 m (+81% y-o-y). Winlevi (novel acne drug launched in Nov 2021) is seeing good traction and around 9K prescribing doctors (out of 15K) have prescribed it. We expect sales traction to continue for key brands on improving patient footfall (elective procedures are not yet back to pre-COVID-19 levels), better commercial execution and increasing market size.
Retain Buy rating: We remain positive on Sun’s efforts in the specialty products portfolio, which we believe will likely achieve Ebitda breakeven over the next 2-3 years, resulting in significant operating leverage. We assume specialty sales to be key driver of US sales, with sales CAGR of 17.2% for FY22-25e, while we assume base generic and Taro sales stabilising at current levels.
Sun plans to expand India sales headcount by 10% in FY23e to improve market coverage and de-clutter some marketing divisions. We assume its India segment sustaining above-market growth on new launches and better reach. The outlook remains largely steady for other segments (RoW, emerging markets, API, etc.) barring any short-term fluctuations. Post Q4, we adjust our estimates per current visibility leading to 3.3%/3.5% cuts in EPS for FY23/24e. Our TP is Rs 1,040 (from Rs 1,075).
猜你喜欢
- Will the strong GDP numbers propel Nifty to claim a new high- 8 things to know before the share market opens
- Will Nifty trade above 21,700 levels or fall ahead- See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- No extra tariffs on steel exports to US
- Will Nifty continue the winning streak to rise above 19900- 8 things to know before share market opens
- XPoSat Launch- India’s Giant Leap in X-Ray Astronomy
- Nifty to test 18400 again or bears to drag index below 18100- 7 things to know before market opening bell
- Buy HUDCO, Syngene International to pocket short-term gains; Nifty must hold above 18,200 for upmove
- Your queries- Loans; Brother-sister duo is not automatically given loan
- Yogi’s Tourism Agenda- Helicopter connectivity and dedicated veterinarians for UP’s wildlife sanctuaries – Details here